2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Profiling, Treatment Considerations, Drug Development, Drug-Drug Interactions, Supportive Care, Biological Therapies, Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Immunology, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, ALL, Aggressive Lymphoma, Research, Fundamental Science, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pregnant
PAPER

1335 Recurrent venous thromboembolism after mechanical thrombectomy

Kelsey Bria, MD, Kareena Pansuria, BS2, Melissa Beasley, BS3, Soophia Naydenov, MD, FCCP4, Roger D Yusen, MD, MPH5, Pavan Kavali, MD6, Kristen Marie Sanfilippo, MD, MPHS7
1 Washington University In Saint Louis, Saint Louis, Missouri, United States
2 University of Kentucky School of Medicine, Bowling Green, Kentucky, United States
3 Washington University In Saint Louis, Saint Louis, Missouri, United States
4 Washington University In Saint Louis, Saint Louis, Missouri, United States
5 Washington University In Saint Louis, Saint Louis, Missouri, United States
6 Washington University In Saint Louis, Saint Louis, Missouri, United States
7 Washington University In Saint Louis, Saint Louis, Missouri, United States

Introduction
Pulmonary embolism (PE) causes significant morbidity and mortality despite advances in management. Anticoagulant therapy remains a cornerstone of treatment, but an expanding body of evidence supports the use of percutaneous mechanical thrombectomy for patients with impending or active cardiopulmonary failure. Prospective studies have demonstrated low rates of in-hospital mortality and other adverse events, as well as rapid improvements in hemodynamic measures following thrombectomy. Much of the extended follow-up in these prospective studies has focused on quality-of-life measures and severe post-PE complications, such as chronic thromboembolic pulmonary hypertension (CTEPH). However, long-term data describing other clinically important outcomes after mechanical thrombectomy (e.g., recurrent PE, major bleeding, etc.) remain limited. We thus aimed to evaluate the rates of recurrent PE and identify predictors associated with recurrent PE in patients who underwent mechanical thrombectomy for intermediate- or high-risk (American Heart Association/American College of Cardiology [AHA/ACC] classes C-E) PE. In addition, we evaluated the rates of major bleeding within 30 days of mechanical thrombectomy.

Methods
We performed a retrospective cohort study of patients at Barnes Jewish Hospital with a Pulmonary Embolism Response Team (PERT) activation between January 2021 and May 2026. Adult patients with intermediate- or high-risk PE who received therapeutic anticoagulation within 24 hours of diagnosis and underwent mechanical thrombectomy were included. Utilizing our prospective PERT database, we performed manual chart review to identify the outcomes of interest: recurrent PE within 6 months of hospital discharge and International Society of Thrombosis and Haemostasis (ISTH) major bleeding within 30 days of mechanical thrombectomy. Outcomes were adjudicated by at least two reviewers. Univariate logistic regression was performed to identify candidate variables associated with recurrent PE. Candidate variables were subsequently evaluated using Cox proportional hazards modeling to identify factors independently associated with recurrent PE. Patients who died before recurrent PE were censored at the time of death.

Results
Between January 2021 and May 2026, 955 independent PERT activations occurred. A total of 140 patients (14.7%) underwent mechanical thrombectomy. Recurrent PE after mechanical thrombectomy occurred in 10 patients (7.1%) within 6 months of hospital discharge. All-cause mortality over the same timeframe occurred in 19 patients (13.6%), including 12 (8.6%) with PE-related death. 30 (21.4%) ISTH major bleeding events occurred, 17 (56.7%) of which were procedure related. In univariate analysis, younger age (OR per year increase in age 0.95, 95% CI 0.91–0.99, p=0.014) and active smoking (OR 5.22, 95% CI 1.38–19.77, p=0.015) were associated with recurrent PE, whereas hypertension was inversely associated (OR 0.16, 95% CI 0.033–0.79, p=0.024). African American race demonstrated a nonsignificant trend toward an association (OR 4.01, 95% CI 0.99–16.26, p=0.052). In the multivariate Cox proportional hazards model, only younger age remained independently associated with recurrent PE (aHR 0.95, 95% CI 0.91– 0.99, p=0.040).

Conclusion
In patients with intermediate- and high-risk (AHA/ACC classes C-E) PE who had a PERT activation and underwent mechanical thrombectomy, we observed high rates of 6-month recurrent PE and 30-day ISTH major bleeding. Younger age was independently associated with recurrent PE. Given the small size of the cohort, we consider these findings as hypothesis-generating and recommend further evaluation in larger cohorts.

Kelsey Bria, MD: No relevant conflicts of interest to declare.